http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008029031-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f08a7dd141d8b0e7453e2ac67360eeda
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6851
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
filingDate 2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3a933106b7f16a2f191e72605337dd4
publicationDate 2008-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008029031-A2
titleOfInvention Pharmacodiagnostic test targeting oncology
abstract A first objective of the present invention is to demonstrate a method for the detection and prognosis of cancer and of its metastatic potential. Preferably, the cancer is selected from breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, a sarcoma and a leukaemia, without being limited thereto. One aspect of the present invention consists of the use of the LIV21 complex as a prognostic indicator for cancer and in the therapeutic monitoring thereof. The LIV21 complex is defined in terms of the extract of proteins and peptides studied by Maldi and ESI MS/MS or Maldi Tof/Tof mass spectrometry. Said extract was obtained by attachment of the LIV21 complex to one of these LIV21 polyclonal antibodies. The LIV21 complex is also defined in terms of its overall mass spectrometry profile (Figure 5) and the number and the molecular weight of the bands of protein extracts obtained as a function of the temperature to which the sample is subjected and the migration conditions described. Another aspect is the use of biochips for the pharmacodiagnosis of oncological pathologies and of neurodegeneration.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10718029-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2950076-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101963617-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101963617-B
priorityDate 2006-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0164736-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006095086-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226438198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6694
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6106
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128912572
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405549
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444795
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129888650
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423408
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4939
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID857
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID42113
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID28280
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406479
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6083
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397217
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8843
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129630656
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127770141
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395986

Total number of triples: 45.